


-39-

Claims

1. A morpholine derivative of formula



and a pharmaceutically suitable acid addition salt thereof.


5

2. The compound of formula I, which is 5-ethyl-4-methyl-*N*-[4-[(2*S*) morpholin-2-yl]phenyl]-1*H*-pyrazole-3-carboxamide.


10

3. A process for the manufacture of the compound of formula I according to claims 1 and 2, which process comprises

- a) cleaving off the N-protecting group (PG) from compounds of formula



to a compound of formula



15

wherein PG is a N-protecting group, selected from $-C(O)O$ -tert-butyl (BOC), and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

4. The compound of formula I according to claims 1 and 2 for use as therapeutically active substance.
5. The compound of formula I according to claims 1 and 2 for use in the treatment
5 of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, schizophrenia, Parkinson's disease, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, addiction, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and
10 malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
6. The compound of formula I according to claims 1 and 2 for use in the treatment of schizophrenia, bipolar disorder or depression.
- 15 7. A pharmaceutical composition comprising the compound of formula I according to claims 1 and 2 and pharmaceutically acceptable excipients.
8. The use of a compound of formula I according to claims 1 and 2 for the
20 preparation of a medicament for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, schizophrenia, Parkinson's disease, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, addiction, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption
25 and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
9. A method for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders,
30 schizophrenia, Parkinson's disease, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, addiction, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders, which

-41-

method comprises administering an effective amount of a compound of formula I as claimed in claims 1 and 2.

10. The invention as hereinbefore described.